▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3780 by analyst upside · 2026-09-29
VTRS
Viatris Inc.
Healthcare · Market Cap $21B · P/E 0x
ANALYST PRICE TARGET
+6.2%
implied upside to consensus target
Current Price $18.27
Consensus Target $19.4
Bull Target $25.0
Bear Target $13.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
3
Sell
1
52-Week Low $9.55
52-Week High $18.39
YTD Return +50.1%
FUNDAMENTALS
Market Cap $21B
P/E Ratio (TTM) N/A
Forward P/E 6.8x
EPS (TTM) $-0.38
PEG Ratio 3.24
Dividend Yield 2.69%
Revenue (TTM) $14.7B
Profit Margin -2.8%
52-WEEK RANGE
52-Week Low $9.55
52-Week High $18.39
Current Price $18.27
Bear Target $13.0
Bull Target $25.0
● Now $18.27 ● Target $19.4
TRADING DATA
Avg Volume 9.3M
YTD Return +50.1%
Analyst Count 10
Consensus Buy
Upside to Target +6.2%
Last Updated 2026-09-29

ANALYST SUMMARY

Viatris Inc. (VTRS) is currently trading at $18.27 with a Wall Street consensus price target of $19.4, implying potential upside of 6.2% over the next 12 months. 10 analysts currently cover VTRS, with a consensus rating of Buy - 60% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $25.0, while the most cautious has a target of $13.0.

VTRS operates in the Healthcare sector with a market capitalisation of $21B. The stock is up 50.1% year-to-date and is currently trading near the upper end of its 52-week range of $9.55 – $18.39.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

UTHR +31.4%
United Therapeutics Corporation
$21B · P/E 17.4x · Buy
EXEL -8.0%
Exelixis, Inc.
$14B · P/E 18.3x · Hold
THC +10.4%
Tenet Healthcare Corporation
$21B · P/E 10.0x · Buy
MEDP -5.5%
Medpace Holdings, Inc.
$17B · P/E 36.4x · Hold
GMAB +10.7%
Genmab A/S
$22B · P/E 28.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for VTRS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer ● Initiated
Outperform 2026-09-23 14% win rate (7 calls)
Piper Sandler - Reiterated
Neutral → Neutral 2026-09-16 14% win rate (7 calls)
Leerink Partners ● Initiated
Outperform 2026-09-09 29% win rate (7 calls)
Argus Research - Reiterated
Buy → Buy 2026-09-08 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-05-19 Building track record
JP Morgan - Reiterated
Neutral → Neutral 2026-05-08 43% win rate (7 calls)
Truist Securities - Reiterated
Buy → Buy 2026-05-08 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-03-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
49
out of 100
Coverage depth
18/30
Consensus clarity
17/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →